Supergoop! appoints Melis del Rey as Chief Executive Officer
The appointment is a strategic focus on leveraging experienced leadership to strengthen brand presence and consumer engagement worldwide.
USA – Supergoop! has announced the appointment of Melis del Rey as its new Chief Executive Officer and Board Director, with her leadership role effective from December 8, 2025.
Melis del Rey brings over 20 years of experience in the global beauty and consumer products industry, specializing in brand building, beauty technology innovation, and scaling businesses through strong retail partnerships to drive shared growth.
This appointment marks a significant step for Supergoop! aims to expand its global impact and continue reshaping consumer attitudes toward sunscreen.
Del Rey succeeds Gregory Polcer, who has been serving as Interim CEO since May 2025.
Polcer will support del Rey during the transition and will remain on Supergoop!’s Board of Directors.
Edgar Huber, Chairman of the Board at Supergoop!, praised Melis del Rey, stating, “Melis is a dynamic and visionary leader with a proven track record of building global brands, strengthening retail partnerships, and delivering exceptional consumer experiences,”
“Her innovative approach to brand building and deep expertise across beauty, e-commerce, and omnichannel strategy make her uniquely suited to lead Supergoop! into its next era of growth.”
This leadership change is expected to accelerate Supergoop!’s growth and innovation trajectory.
Melis del Rey’s extensive experience in beauty and retail innovation is poised to help the New York-based brand deepen its mission of changing how people think about and use sunscreen globally.
Gregory Polcer expressed confidence in the company’s strong position, passionate team, and loyal consumer base, trusting that Melis will drive continued achievements under her leadership.
Meanwhile, the U.S. Food and Drug Administration (FDA) issued a warning letter to the skincare brand Supergoop! regarding its “PLAY SPF 50 BODY MOUSSE” sunscreen product.
The FDA’s primary concern is that this mousse sunscreen is classified as a drug under federal law due to its claims and intended uses, but has not received the required FDA approval to be marketed as such.
According to the FDA, The “PLAY SPF 50 BODY MOUSSE” is considered a drug under sections 201(g)(1)(B) and 201(g)(1)(C) of the Federal Food, Drug, and Cosmetic (FD&C) Act because it is intended to prevent sunburn and protect the skin from harmful UV rays, thereby affecting the structure and function of the body.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
